DSpace Arşivi :: by Yazar "Caloglu, Murat" değerine göre listeleniyor

Yazar "Caloglu, Murat" seçeneğine göre listele

Listeleniyor 1 - 20 / 45

Acute histopathological responses of testicular tissues after different fractionated abdominal irradiation in rats
(Informa Healthcare, 2015) Akdere, Hakan; Caloglu, Vuslat Yurut; Tastekin, Ebru; Caloglu, Murat; Turkkan, Gorkem; Mericliler, Meric; Burgazli, Kamil Mehmet
Purpose: To compare the effects of different fractionated doses of abdominal radiation therapy on acute histopathological responses of testicular tissues in rats. Methods: Thirty-three 3-week-old Wistar albino rats were randomized into 6 groups: group 1 (n = 5), control; group 2 (n = 4), hypofractionated total abdominal irradiation (TAI) of 6 Gy/1 fraction/day for 2 days; group 3 (n = 6), hypofractionated TAI of 4 Gy/1 fraction/day for 3 days; group 4 (n = 6), hypofractionated TAI of 3 Gy/1 fraction/day for 4 days; group 5 (n = 6), conventionally fractionated TAI of 2 Gy/1 fraction/day for 6 days; group 6 (n = 6), conventionally fractionated TAI of 1.7 Gy/1 fraction/day for 7 days. Mean epithelial length and diameter of seminiferous tubules of testicular tissues were determined after euthanasia. Results: Initially, a highly significant decrease in both the mean tubular diameter and epithelial height of the seminiferous tubules was demonstrated in all irradiated rats compared with the control group. No significant differences regarding both damage parameters were found between different hypofractionated radiation therapies. Both conventional radiation therapies reduced the epithelial height and mean diameter of the seminiferous tubules to a lesser extent when compared with 6 Gy/1 fraction/day hypofractionated therapy. It was further shown that parameter values were comparable between rats that received 3 Gy/day hypofractionated therapy and rats that received either of the two conventional therapies. Furthermore, although 4 Gy/day hypofractionation decreased tubular diameter and epithelial length to a greater degree compared with the conventional therapy of 1.7 Gy/1 fraction/day, no statistically significant difference was found when compared with conventional therapy of 2 Gy/1 fraction/day. Additionally, no statistically significant difference was demonstrated between the two types of conventional radiotherapy application. Conclusion: The present study demonstrated that hypofractionated abdominal irradiation leads to more prominent tissue damage in the testes than conventional irradiation.
An ambiguous phenomenon of radiation and drugs: Recall reactions
(Karger, 2007) Caloglu, Murat; Yurut-Caloglu, Vuslat; Cosar-Alas, Rusen; Saynak, Mert; Karagol, Hakan; Uzal, Cem
The term 'radiation recall' describes an acute inflammatory reaction in previously irradiated areas after the administration of certain inciting systemic agents. It was first described in 1959 by D'Angio that dermatitis is related to the application of actinomycin D on the skin. Though this reaction occurs frequently on the skin, it may also be seen in the oral mucosa, the larynx, esophagus, small intestine, lungs, muscle tissue, and brain. Most drugs associated with recall reactions are cytotoxics, however, several other drugs may also elicit the phenomenon. Although this phenomenon is well known, its etiology is not understood. Radiation recall reactions are generally associated with megavoltage radiotherapy. The time interval between the completion of radiotherapy and the recall reaction ranges from days to years. The recall reaction occurs on average 8 days (3 days to 2 months) after the application of the promoting agent. Although no standard treatment exists, some authors suggest discontinuation of the inciting drug and the use of corticosteroids or nonsteroidal anti-inflammatory agents.
Amifostine use in radiation-induced kidney damage
(Springer Heidelberg, 2008) Kaldir, Mine; Cosar-Alas, Rusen; Cermik, Tevfik Fikret; Yurut-Caloglu, Vuslat; Saynak, Mert; Altaner, Semsi; Caloglu, Murat
Purpose: To assess the degree of protective effects of amifostine on kidney functions via semiquantitative static renal scintigraphy and histopathologic analysis. Material and Methods: 30 female albino rats were divided into three equal groups as control (CL), radiotherapy alone (RT), and radiotherapy + amifostine (RT+AMI). The animals in the CL and RT groups were given phosphate-buffered saline, whereas the animals in the RT+AMI group received amifostine (200 mg/kg) by intraperitoneal injection 30 min before irradiation. RT and RT+AMI groups were irradiated with a single dose of 6 Gy using a Co-60 unit at a source-skin distance of 80 cm to the whole right kidney. They were followed up for 6 months. CL, RT, and RT+AMI groups underwent static kidney scintigraphy at the beginning of the experiment and, again, on the day before sacrificing. Histopathologically, tubular atrophy and fibrosis of the kidney damage were evaluated. Results: After irradiation, the median value of right kidney function was 48% (44-49%) and 50.5% (49%-52%) in RT and RT+AMI groups, respectively (p = 0.0002). Grade 1 kidney fibrosis was observed to be 60% in the RT group, while it was only 30% in the RT+AMI group. Grade 2 kidney fibrosis was 30% and 0% in the RT and RT+AMI group, respectively. Grade 1 tubular atrophy was 70% and 50% in the RT and RT+AMI group, respectively. Grade 2 tubular atrophy effect was the same in both groups (10%). Conclusion: Static kidney scintigraphy represents an objective and reproducible method to noninvasively investigate kidney function following irradiation. Amifostine produced a significant reduction in radiation-induced loss of renal function.
THE APPLICATION OF CRANIAL PROPHYLACTIC RADIOTHERAPY IN CHILDREN WITH ALL HAS AN EFFECT ON NEUROCOGNITIVE FUNCTION
(Wiley-Liss, 2009) Gorker, Isyk; Orhaner, Betuel Biner; Caloglu, Vuslat Yueruet; Aygolu, Fuesun; Uzal, Cem; Caloglu, Murat; Uyanik, Vesile
[Abstract Not Available]
The Better Performance Status, the Better Outcome: Laryngeal Carcinoma Treated with Definitive Radiotherapy
(B C Decker Inc, 2008) Yurut-Caloglu, Vuslat; Caloglu, Murat; Turan, Fatma Nesrin; Ibis, Kamuran; Karagol, Hakan; Kocak, Zafer; Uzal, Cem
Purpose: To evaluate the prognostic factors affecting locoregional control (LRC) and overall survival (OS) of patients with laryngeal carcinoma who were not candidates for surgical treatment due to tumour or host factors but were treated with definitive radiotherapy (RT). Patients and Methods: Sixty-three consecutive patients, treated with definitive RT between 1999 and 2005, were retrospectively analyzed. All patients had histologically proven squamous cell carcinomas of the larynx. The median age was 62 years (range 43-83 years). Follow-up ranged from 22 days to 68 months (median 32 months). Results: The LRC rates at 2 and 5 years were 70% and 48%. The 2- and 5-year OS rates were 65% and 40%. No statistically significant relationship was found between World Health Organization performance status score (WHO PS) and age (p = .21), tumour site (p = .42), overall stage (p = .11), T stage (p = .19), and N stage (p = .69). Multivariate analyses showed that a WHO PS score >= 2 (p < .0001) and RT treatment time >= 50 days (p = .0172) significantly decreased LRC. Moreover, a WHO PS score >= 2 (p < .0001), RT treatment time >= 50 days (p = .0138), and RT dose < 66 Gy (p = .04) were significantly negative prognostic factors on OS. Conclusion: Definitive RT, in patients with early- and more advanced-stage squamous cell carcinoma of the larynx, is an important treatment option. It is clear that patients with good pretreatment PS would get better results from definitive RT.
A brief look at the evaluation of the development and effectiveness of cytotoxic chemotherapy in advanced non-small-cell lung cancer
(Kare Publ, 2010) Uzunoglu, Sernaz; Karagol, Hakan; Tanriverdi, Ozgur; Cicin, Irfan; Caloglu, Murat; Kocak, Zafer
Systemic chemotherapy for patients with advanced-stage non-small-cell lung cancer prolongs survival and palliates symptoms, when compared with the best supportive care alone. However, the results of standard cytotoxic regimens are not yet satisfactory. As the effectiveness in the treatment of refractory disease is low, it still remains critical to better understand and develop new treatment options for refractory disease. Within the second-line therapeutic approaches, there are new chemotherapeutic schemes as well as molecular-targeted treatment options that block the epidermal growth factor receptor or angiogenesis. Future research efforts should focus on identifying prognostic and predictive markers of benefit not only for the standard cytotoxic agents, but also for the new target-driven agents currently.
BURNED-OUT TUMOR OF THE TESTIS: CASE REPORT
(Aves, 2008) Kaplan, Mustafa; Karagol, Hakan; Altaner, Semsi; Aktoz, Tevfik; Caloglu, Murat; Inci, Osman
Introduction: Burned-out testicular tumor is a rare entity. The term burned-out tumor of the testis describes a spontaneously and completely regressed testicular tumor which presents by its metastases to retroperitoneum, mediastinum, lymph nodes such as supraclavicular, cervical and axillary. This condition is different and less common from the primary extragonadal germ cell tumors. Many pathologists are not familiar with the findings that support a diagnosis of burned-out primary in a patient with metastatic germ cell tumor. We report 2 cases of burned-out testicular tumors to illustrate the clinical, radiological and histopathological features. Burned-out testicular tumor must be considered in a patient with retroperitoneal lymph node involvement and histology of germ-cell tumor in the absence of palpable testicular tumor. Metastases should be treated according to the histology and clinical stage of the tumor. Radical orchiectomy must be performed because of the high rate of persistent testicular tumor.
Comparison of Protective Effects of L-Carnitine and Amifostine on Radiation-induced Toxicity to Growing Bone: Histopathology and Scintigraphy Findings
(Asian Pacific Organization Cancer Prevention, 2010) Yurut-Caloglu, Vuslat; Durmus-Altun, Gulay; Caloglu, Murat; Usta, Ufuk; Saynak, Mert; Uzal, Cem; Cosar-Alas, Rusen
Purpose: The aim of the present study was to evaluate the radioprotective efficacy of L-carnitine (LC) in growing bones in comparison to amifostine. Materials and Methods: Sixty two-week-old Wistar albino rats were randomly assigned to six equal groups: Group 1, control (CONT); Group 2, irradiation alone (RT); Group 3, amifostine plus irradiation (AMI+RT); Group 4, L-carnitine plus irradiation (LC+RT); Group 5, amifostine alone (AMI); Group 6, L-carnitine alone (LC). The rats in the AMI+RT, LC+RT and RT groups were irradiated individually with a single dose of 20 Gy to the left femur. LC (300mg/kg) and amifostine (200mg/kg) were applied 30 min before irradiation. The animals were scanned for bone area, mineral content and bone mineral density (BMD) by DEXA and the 99mTc methylene diphosphonate uptake ratio (MUR) was calculated by bone scintigraphy. Histopathological analysis of bone and cartilage was also carried out after euthanasia. Results: Pretreatment with LC or amifostine reduced the radiation-induced damage in growing bone (p=0.007 and p=0.04 respectively) and in the epiphysial cartilage (p=0.002 and p=0.015 respectively). The protective effect of LC was similar to that of amifostine on both growing bone and on the epiphysial cartilage. The mean left-femur BMD values were significantly higher in the LC+RT (p=0.02) and AMI+RT (p=0.01) groups than in the RT group. but did not differ with the two protective agents. Pretreatment with AMI (p=0.002) and LC (p=0.01) improved the MUR. Conclusions: L-carnitine is equally as effective as amifostine at protecting growing bone against single dose irradiation damage.
Comparison of the protective roles of L-carnitine and amifostine against radiation-induced acute ovarian damage by histopathological and biochemical methods
(Medknow Publications & Media Pvt Ltd, 2015) Yurut-Caloglu, Vuslat; Caloglu, Murat; Eskiocak, Sevgi; Tastekin, Ebru; Ozen, Alaattin; Kurkcu, Nukhet; Oz-Puyan, Fulya
Purpose: The aim of this study was to compare the radioprotective efficacies of L-carnitine (LC) and amifostine against radiation-induced acute ovarian damage. Materials and Methods: Forty-five, 3-month-old Wistar albino rats were randomly assigned to six groups. Control (CONT, n = 7); irradiation alone RT: radiation therapy (RT, n = 8); amifostine plus irradiation (AMI + RT, n = 8); LC plus irradiation (LC + RT, n = 8); LC and sham irradiation (LC, n = 7); and amifostine and sham irradiation (AMI, n = 7). The rats in the AMI + RT, LC + RT and RT groups were irradiated with a single dose of 20 Gy to the whole abdomen. LC (300 mg/kg) and amifostine (200 mg/kg) was given intraperitoneally 30 min before irradiation. Five days after irradiation, both antral follicles and corpus luteum in the right ovaries were counted, and tissue levels of malondialdehyde (MDA) and advanced oxidation protein product (AOPP) were measured. Results: Irradiation significantly decreased antral follicles and corpus luteum (P:0.005 and P < 0.0001). LC increased the median number of antral follicles and corpus luteum (P:0.009 and P < 0.0001, respectively). Amifostine improved median corpus luteum numbers but not antral follicle (P < 0.000, P > 0.05). The level of MDA and AOPP significantly increased after irradiation (P = 0.001 and P < 0.0001, respectively). MDA and AOPP levels were significantly reduced by LC (P:0.003, P < 0.0001) and amifostine (P < 0.0001, P:0.018). When comparing CONT group with AMI + RT and LC + RT groups, MDA and AOPP levels were similar (P > 0.005). The levels of both MDA and AOPP were also similar when LC + RT is compared with AMI + RT group (P > 0.005). Conclusions: L-carnitine and amifostine have a noteworthy and similar radioprotective effect against radiation-induced acute ovarian toxicity.
The comparison of weekly and 3-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic SCCHN
(Oxford Univ Press, 2006) Uygun, Kazim; Karagol, Hakan; Caloglu, Murat; Cicin, Irfan; Caloglu, Vuslat Y.; Uzunoglu, Sernaz; Saip, Pinar
[Abstract Not Available]
The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck
(Springer, 2009) Uygun, Kazim; Bilici, Ahmet; Karagol, Hakan; Caloglu, Murat; Cicin, Irfan; Aksu, Gorkem; Fayda, Merdan
Several studies have shown that the concurrent administration of chemotherapy (CHT) and radiotherapy (RT) is superior to RT alone in patients with inoperable non-metastatic squamous cell carcinoma of the head and neck (InSCCHN). We compared the efficacy and safety profile of RT and concurrent cisplatin CHT given in two different schedules to patients with previously untreated InSCCHN. Fifty patients with previously untreated InSCCHN admitted to our oncology department were included in the study. Thirty of 50 (60%) patients with a younger age or good performance status (PS) (ECOG 0-1) received cisplatin 100 mg/m(2) on a 21-day schedule (group A). Other 20 (40%) patients with older age or poor PS (ECOG 2) received cisplatin 40 mg/m(2) on a 7-day schedule (group B). Each of the 50 patients received concurrent conventional dose RT according to primer tumor location. The median follow-up is 12 months for group A and 12.5 months for group B. Twenty-eight (93.3%) patients in group A and 18 (90%) in group B were evaluable for response. The complete response rate was 50% in group A and 40% in group B (P > 0.05). The objective response rate was 92% in group A and 90% in group B (P > 0.05). All grade 3-4 toxic events were seen in 16 (53.3%) of group A patients and 8 (40%) of group B patients (P > 0.05). Comparison between two treatment modalities appears to result in statistically similar response rates and adverse event profile. A randomized phase III trial is required to confirm the safety and efficacy of weekly cisplatin therapy in patients with poor PS and/or older age at diagnosis.
Cutaneous metastasis of epidermoid carcinoma of the larynx: a case report
(Kare Publ, 2006) Ibis, Kamuran; Ibis, Cem; Yurut-Caloglu, Vuslat; Altaner, Semsi; Caloglu, Murat; Karagol, Hakan; Cosar-Alas, Rusen
The frequency of distant metastasis of epidermoid carcinoma of the larynx is between 6.5-7.2%. The common sites of metastasis are lung, liver and bone. Cutaneous metastasis is very rare. A 56-year-old male with locally advanced larynx carcinoma who received curative radiochemotheraphy a year ago was presented to our department with subcutaneous nodular lesions, and fatigue. Physical examination revealed 0.5 cm sized, and 1x1cm sized subcutaneous nodular lesions in the right arm, and in the parasternal area, respectively. Histopathologic examination confirmed the skin metastasis of epidermoid carcinoma of the larynx. The patient has profound anemia, hypercalcemia, hypernatremia, and hyperglicemia with complicated diabetic foot. Although the symptomatic treatment began immediately, the patient died on the third day of hospitalisation. Cutaneous metastasis may be the first sign of local failure, of distant metastasis, or even of the undetected laryngeal carcinoma with poor prognosis.
Does low-dose X-irradiation promote mineralization of fracture callus in a rat model?
(Springer, 2009) Heybeli, Nurettin; Caloglu, Murat; Yurut-Caloglu, Vuslat
[Abstract Not Available]
The effect of low molecular weight heparin on survival in patients with cancer
(Kare Publ, 2006) Saynak, Mert; Yurut-Caloglu, Vuslat; Bayir, Gulden; Caloglu, Murat; Uzal, Cem
The association between cancer and venous thromboembolism (VTE) is well established. Of all new venous tromboembolism, approximately 20% are associated with active malignancy. In these cases, the pathogenic mechanisms of thrombosis involve a complex interaction between tumour cells, the haemostatic system, and charateristics of the patient. Anticoagulants are the mainstay therapy for the prevention and treatment of acute VTE. The natural history of VTE is more agressive and anticoagulant treatment failure is more frequent in cancer patients than in patients without cancer. Recently, the results of new prospective randomized clinical trials to evaluate the effect of low-molecular-weight heparin on cancer survival have become available. The results suggest a benefit from treatment, particularly in patients with nonadvanced disease. However, these results are not conclusive and require further research.
The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
(Humana Press Inc, 2007) Karagol, Hakan; Saip, Pinar; Uygun, Kazim; Caloglu, Murat; Eralp, Yesim; Tas, Faruk; Aydiner, Adnan
Background: Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma. Patients and Methods: A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer. Results: Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and >= 12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression-free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94). Conclusion: Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to confirm the value of the drug in patients presenting these clinical settings.
The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer [Meeting Abstract]
(Elsevier, 2006) Karagol, Hakan; Saip, Pinar; Uygun, Kazim; Caloglu, Murat; Eralp, Yesim; Tas, Faruk; Aydiner, Adnan
[Abstract Not Available]
Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma - A retrospective single-center study
(Wiley, 2007) Cicin, Irfan; Karagol, Hakan; Uzunoglu, Sernaz; Uygun, Kazim; Usta, Ufuk; Kocak, Zafer; Caloglu, Murat
BACKGROUND. The study was conducted with the aim of reviewing the clinical features, therapy, and natural course of patients with extrapulmonary small-cell carcinoma (EPSCC) and small-cell lung carcinoma (SCLC) to better define current concepts regarding EPSCCs. METHODS. The medical records of patients with proven diagnosis of small-cell carcinoma (SmCQ between January 1999 and May 2006 were retrospectively reviewed. A total of 65 SmCC cases were included in the study (11 [17%] cases of EPSCC and 54 [83%] cases of SCLQ. RESULTS. Progression-free survival of all patients with EPSCC and patients with-extensive EPSCC disease was 7 months (95% confidence interval 10], 0.58-13.42) and 7 months (95% Cl, 4.71-13.29), respectively. Overall survival of all patients with EPSCC and patients with extensive EPSSC disease was 32 months (95% CI, 18.74-45.26) and 28 months (95% Cl, 12.24-43.76), respectively. Progression-free survival and overall survival for all patients with SCLC were 5 months (95% Cl, 2.26-7.74) and 10 months (95% Cl, 5.95-14.05), respectively. Progression-free survival and overall survival for patients with extensive disease were 3 months (95% Cl, 4.71-13.29) and 5 months (95% CI, 3.33-6.67), respectively. Overall survival was significantly better in all patients with EPSCC and in patients with extensive EPSCC disease compared with A patients with SCLC and patients with extensive SCLC disease (P =.014, P -.004, respectively). Early death and brain metastasis were observed in a higher number of patients with SCLC compared with EPSCC) however, these results were not statistically significant (P 33 and P =.076, respectively). Smoking history was significantly less in the FPSCC group (P <.0001). CONCLUSIONS. EPSCC is usually treated similarly to SCLC. However, this study suggests some differences such as etiology, clinic course, survival, frequency of brain metastases, and early death between these entities. These possible differences may influence the choice of therapeutic approach. Cancer 2007; 110: 106&76. (c) 200 7 American Cancer Society.
Factors affecting local control, distant recurrence and survival in patients with locally advanced bladder cancer treated by definitive radiotherapy or chemoradiotherapy
(Kare Publ, 2006) Caloglu, Murat; Yurut-Caloglu, Vuslat; Saynak, Mert; Cosar-Alas, Rusen; Karagol, Hakan; Kaplan, Mustafa; Ibis, Kamuran
OBJECTIVES Treatment results of 34 patients with bladder cancer admitted to Department of Radiation Oncology, Medicine Faculty of Trakya University between October 1997 and June 2005 were retrospectively analyzed. Prognostic factors associated with survival were determined. METHODS Their median age was 69 years (range 44-93). Thirty patients (88%) were male and 4 patients (12%) were female. Histopathological diagnosis was transitional cell carcinoma in 20 (59%) patients. Chemotherapy was administered concomitantly with radiotherapy to the 11 (32.35%) of the patients. The median radiotherapy dose was 62.5 (35-68) Gy. The median follow-up was 22 months (5-76 months). Median survival and median disease-free survival were 14.2 months (3.8-57.5) and 10 months (0-55), respectively. RESULTS Three years loco-regional control, metastasis free survival, disease free survival and overall survival rates were 76.59 , 72.2%, 55% and 41.1%, respectively. Epidermoid carcinoma histopathology (p=0.002), not performing concomitant chemotherapy (p=0.003), applying carboplatin instead of cisplatin with radiotherapy (p=0.004) and not conducting complete TURB (p=0.008) were significant poor prognostic factors on loco-regional control. Undifferentiated cell type (p=0.012) and not performing concomitant chemotherapy (p=0.046) were significant adverse factors on distant metastases. Factors that affect overall survival were tumor in stage T-4 (p=0.05), hemoglobin value below 10 g/dl (p=0.032) and not performing concomitant chemo-radiotherapy (p=0.017) and complete TURB (p=0.049). CONCLUSION Complications of radiotherapy were acceptable. For the treatment of muscle invasive locally advanced bladder cancer, RT combined with cisplatin is an acceptable treatment option. Moreover, complete TURB before RT is important both for local control and for survival.
HISTOPATHOLOGICAL AND SCINTIGRAPHIC COMPARISONS OF THE PROTECTIVE EFFECTS OF l-CARNITINE AND AMIFOSTINE AGAINST RADIATION-INDUCED LATE RENAL TOXICITY IN RATS
(Wiley-Blackwell Publishing, Inc, 2009) Caloglu, Murat; Yurut-Caloglu, Vuslat; Durmus-Altun, Gulay; Oz-Puyan, Fulya; Ustun, Funda; Cosar-Alas, Rusen; Saynak, Mert
The aim of the present study was to compare the protective effects of l-carnitine and amifostine against radiation-induced late nephrotoxicity using technetium-99m diethylenetriaminepentaacetic acid scintigraphy and histopathological examination. Seventy-one Albino rats were randomly divided into six groups as follows: (i) AMI + RAD (n = 15), 200 mg/kg, i.p., amifostine 30 min prior to irradiation (a single dose of 9 Gy); (ii) LC + RAD (n = 15), 300 mg/kg, i.p., l-carnitine 30 min prior to irradiation; (iii) LC (n = 10), 300 mg/kg, i.p., l-carnitine 30 min prior to sham irradiation; (iv) AMI (n = 10), 200 mg/kg, i.p., amifostine 30 min prior to sham irradiation; RAD (n = 11), 1 mL/kg, i.p., normal saline 30 min prior to irradiation; and (vi) control (n = 10), 1 mL/kg, i.p., normal saline 30 min prior to sham irradiation. Scintigraphy was performed before treatment and again 6 months after treatment. Kidneys were examined by light microscopy and a histopathological scoring system was used to assess the degree of renal damage. The main histopathological findings were proximal tubular damage and interstitial fibrosis. Glomerular injury was similar in all groups. Tubular degeneration and atrophy were less common in the AMI + RAD group than in the RAD group (P = 0.011 and P = 0.015, respectively), as well as in the LC + RAD group compared with the RAD group (P = 0.028 and P = 0.036, respectively). Interstitial fibrosis in the AMI + RAD and LC + RAD groups was significantly less than that in the RAD group (P = 0.015 and P = 0.015, respectively). The highest total renal injury score (9) was seen in the RAD group. On scintigraphy, there were significant differences in post-treatment time to peak count (T(max)) and time from peak count to half count (T(1/2)) values (P = 0.01 and 0.02, respectively) between groups in the right kidney. In the control and RAD groups, the T(1/2) of the right kidney was 8 +/- 2 and 21 +/- 2 min, respectively. The T(max) values for the AMI + RAD and LC + RAD groups (2.8 +/- 0.2 and 3.2 +/- 0.2 min, respectively) were similar to those in the control group (2.5 +/- 0.3 min). Based on the results of the present study, l-carnitine and amifostine have comparable and significant protective effects against radiation-induced late nephrotoxicity.
The histopathological comparison of L-carnitine with amifostine for protective efficacy on radiation-induced acute small intestinal toxicity
(Medknow Publications, 2012) Caloglu, Murat; Caloglu, Vuslat Yurut; Yalta, Tulin; Yalcin, Omer; Uzal, Cem
Background: The aim of the study was to compare the protective efficacy of l-carnitine (LC) to amifostine on radiation-induced acute small intestine damage. Materials and Methods: Thirty, 4-week-old Wistar albino rats were randomly assigned to four groups - Group 1: control (CONT, n = 6), Group 2: irradiation alone (RT, n = 8), Group 3: amifostine plus irradiation (AMIRT, n = 8), and Group 4: l-Carnitine plus irradiation (LCRT, n = 8). The rats in all groups were irradiated individually with a single dose of 20 Gy to the total abdomen, except those in CONT. LC (300 mg/kg) or amifostine (200 mg/kg) was used 30 min before irradiation. Histopathological analysis of small intestine was carried out after euthanasia. Results: Pretreatment with amifostine reduced the radiation-induced acute degenerative damage (P = 0.009) compared to the RT group. Pretreatment with LC did not obtain any significant difference compared to the RT group. The vascular damage significantly reduced in both of the AMIRT (P = 0.003) and LCRT group (P = 0.029) compared to the RT group. The overall damage score was significantly lower in the AMIRT group than the RT group (P = 0.009). There was not any significant difference between the LCRT and RT group. Conclusions: Amifostine has a marked radioprotective effect against all histopathological changes on small intestinal tissue while LC has limited effects which are mainly on vascular structure.

Yazar "Caloglu, Murat" seçeneğine göre listele

Sayfa Başına Sonuç

Sıralama seçenekleri